Fusing de-identified data and analytics with the right insights can provide a clear picture of a broad range of medical conditions and patient populations, driving efficiency and improving the quality of care for millions of Americans.
Typically, 70% of clinical decisions are made with lab data.1 This reliance on critical findings can help fuel tomorrow’s clinical and commercial strategy for drug development. Data-driven, predictive insights backed by lab data have the ability to dramatically change how pharmaceutical executives make strategic decisions.
With more than 650 active EMR interfaces, Quest enables universal test ordering and high-availability results reporting. Many of our pharma and public health customers have invested in clinical data sets that are particularly relevant to their disease focus. Quest has built a series of collaborations with data providers that enable these clients to link those data sets with matched, de-identified data to help them understand the patient journey, patterns in disease progression, and acuity stratification.
For example, a therapy company may have a cardiovascular pipeline and investment in an events database containing stroke and heart attack data. Quest can leverage its own laboratory data to perform analyses to match relevant biomarkers, so that intervention opportunities and linkages between labs, medication history, claims, and outcomes can be explored. Quest has invested in multiple de-ID collaborators, so our clients can choose from 1 of 6 deidentified output formats, based on their previous investments.
Fusing de-identified data and analytics with the right insights can provide a clear picture of a broad range of medical conditions and patient populations, driving efficiency and improving the quality of care for millions of Americans.
From routine testing to advanced genetic testing, our data covers nearly all therapeutic areas and can be leveraged across the drug development continuum. Quest Diagnostics data represent a diverse selection of therapeutic areas and medical conditions including:
Quest Diagnostics data also feature important insights into key factors like physician specialty, diagnostic code at the time of the last order, and patient demographics.
Quest Diagnostics is committed to protecting the privacy of identifiable health information, while advancing the science of healthcare and empowering better patient health. Throughout all stages of our research and reporting, maintaining patient privacy is paramount.
Our extensive data-collection process includes de-identifying data from multiple sources, which ensures that health information is anonymized. By protecting patient confidentiality while enabling our data scientists to analyze and interpret health trends, we can help our clients make more informed decisions on their journey toward effective disease interventions.
We follow the terms and conditions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) explicitly. Any protected health information (PHI) data is de-identified, stored, and used for legitimate public health purposes in full accordance with the law.
Quest Diagnostics is a covered entity under HIPAA, which, with patient authorization, provides us with the ability to reach out to patients for clinical trial purposes as a care option. Quest also offers the use of our lab data to help identify the right clinically profiled patients who may be eligible for your clinical trials. We can also identify the physicians servicing these patients and reach out to them directly to educate them about your clinical trial.
Contact our pharma solutions experts to design a custom program to accommodate the needs of your study.